KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $9.3 billion.

  • Regeneron Pharmaceuticals' Total Liabilities rose 1065.93% to $9.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 billion, marking a year-over-year increase of 1065.93%. This contributed to the annual value of $9.3 billion for FY2025, which is 1065.93% up from last year.
  • Regeneron Pharmaceuticals' Total Liabilities amounted to $9.3 billion in Q4 2025, which was up 1065.93% from $9.2 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Total Liabilities' 5-year high stood at $9.3 billion during Q4 2025, with a 5-year trough of $5.8 billion in Q1 2021.
  • Over the past 5 years, Regeneron Pharmaceuticals' median Total Liabilities value was $6.9 billion (recorded in 2021), while the average stood at $7.3 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Total Liabilities skyrocketed by 5988.96% in 2021 and then tumbled by 272.08% in 2022.
  • Regeneron Pharmaceuticals' Total Liabilities (Quarter) stood at $6.7 billion in 2021, then fell by 1.73% to $6.6 billion in 2022, then rose by 8.5% to $7.1 billion in 2023, then grew by 18.27% to $8.4 billion in 2024, then rose by 10.66% to $9.3 billion in 2025.
  • Its last three reported values are $9.3 billion in Q4 2025, $9.2 billion for Q3 2025, and $8.3 billion during Q2 2025.